Pharmaceuticals

Amgen to buy leukemia drug developer Micromet for $1.16 billion

27 Jan 2012

Watson acquires Strides Arcolab’s Australian generic unit for Rs1,983 crore

24 Jan 2012

Dishman Pharma acquires French contract research firm Creapharm Parenterals

17 Jan 2012

Valeant Pharmaceuticals raises offer for opthalmic drugs maker ISTA

17 Jan 2012

Novartis restructures US operations, to cut 1,960 jobs

14 Jan 2012

Glenmark wins favourable interim order in deal with Napo

14 Jan 2012

In a significant positive for Glenmark Pharmaceuticals Ltd, its US partner in a drug development and marketing agreement, Napo Pharmaceuticals Inc, will not be able to terminate a deal thanks to an arbitration order

Bristol-Myers to acquire hepatitis C oral drug developer Inhibitex for $2.5 bn

09 Jan 2012

Bristol-Myers Squibb over the weekend said that it will buy Inhibitex Inc, for about $2.5 billion in cash in order to expand its broad hepatitis C portfolio

Alexion Pharma to acquire Enobia for around $1.08 bn

29 Dec 2011

Zydus Cadila acquires Biochem Pharmaceuticals

21 Dec 2011

Medical device maker C R Bard acquires Lutonix

21 Dec 2011

Biocon arm Clinigene in pact with US company for speciality biomarkers

21 Dec 2011

Ranbaxy to pay $500 million to settle USFDA ban

21 Dec 2011

GSK to sell some North American OTC drugs to Prestige Brands for $661 mn

21 Dec 2011

Government extends sops for engineering, pharma and chemical exports

16 Dec 2011

Covidien plans to spin off pharmaceuticals business

16 Dec 2011

Covidien’s $2 billion pharmaceuticals business is among the top 10 generic drug makers in the US

Glenmark to market Crofelemer despite Napo nix

15 Dec 2011

Pfizer battles dwindling Lipitor sales with hike in dividend, stock buy-back plan

13 Dec 2011

AstraZeneca to buy China’s generic maker Guangdong BeiKang Pharma

08 Dec 2011

AstraZeneca to cut 1,150 sales jobs in the US

08 Dec 2011

Ranbaxy to share Lipitor profits with Teva

02 Dec 2011

Teva today acknowledged that it has entered into a profit-sharing deal with Ranbaxy, but did not provide details of what it was doing to earn that money

No immediate gain for Ranbaxy despite Lipitor patent's expiry

30 Nov 2011

Unlimited FDI in pharma sector worries Jena

30 Nov 2011

Merck to pay $950 million to settle Vioxx drug charges

24 Nov 2011

Vioxx was the centre of a long-running probe by the DoJ for Merck having promoted the painkiller without approval

Pfizer to buy skin scarring drugmaker Excaliard Pharmaceuticals

23 Nov 2011

Gilead Sciences to acquire hepatitis C drug developer Pharmasset for $11 bn

21 Nov 2011

Gilead's acquisition of Pharmasset is aimed at  diversifying its portfolio to experimental treatments for the hepatitis C virus